UK center begins bee and wasp venom immunotherapy in dogs

A new option for canine sting allergy is now available in the UK, with the University of Glasgow’s Small Animal Hospital announcing that it has become the first UK center to treat dogs with Hymenoptera venom immunotherapy for severe reactions to bee and wasp stings. The hospital says the treatment has already been used successfully in several patients and positions it as a way to reduce the risk of repeat anaphylaxis rather than simply respond to emergencies after they happen. (gla.ac.uk)

The development builds on a treatment model long used in human allergy care. Glasgow says venom immunotherapy works by administering gradually increasing doses of venom to train the immune system to tolerate future exposure. At its referral service, the process starts with diagnostic testing, followed by a closely monitored induction phase and then long-term maintenance therapy that may continue for at least five years, and in some dogs, potentially for life. (gla.ac.uk)

The university’s announcement ties the UK milestone to a broader evidence base that is still relatively small in veterinary medicine. In a 2023 open-access study on Hymenoptera venom immunotherapy in dogs, 10 dogs with prior sting anaphylaxis underwent treatment using bee and/or wasp venom extracts. The protocol used rush induction over two treatment days, followed by monthly maintenance dosing, with later spacing of injections over time. Seven of the 10 dogs were later evaluated by accidental field stings or in-clinic sting challenge, and none developed systemic reactions; one dog had only local angioedema after re-sting. The same paper reported no adverse events during the maintenance phase, although mild pruritus occurred in two dogs during induction. (mdpi-res.com)

Glasgow’s clinical materials add practical detail that may matter to referring veterinarians. The hospital says blood allergy testing can be initiated by the referring vet, induction is performed onsite with continuous monitoring, and maintenance injections can also be administered by the patient’s local veterinarian. After six months of therapy, the service may perform a controlled bee or wasp sting to assess effectiveness if the pet parent agrees or if no field sting has occurred. (gla.ac.uk)

Professor Ana Rostaher, who leads the treatment at Glasgow, called venom immunotherapy “a major advance” in managing severe insect sting allergy in dogs and said it offers a proactive way to change the patient’s risk profile. In the university’s case example, Amber, a Vizsla from Stratford-upon-Avon, became the first dog treated through the program after a severe bee-sting reaction at home in July 2021, a case her pet parents said left them anxious about future exposure during warmer months and outdoor activity. (gla.ac.uk)

Why it matters: For veterinary teams, the significance is less about novelty alone and more about prevention. Severe sting hypersensitivity is unpredictable, seasonal, and potentially fatal, yet many practices have had little beyond emergency stabilization and avoidance counseling to offer after an index event. Glasgow says almost two-thirds of dogs with one severe reaction may have the same or worse symptoms after another sting, and its dermatology service describes venom immunotherapy as the only preventive strategy currently available for recurrent sting-triggered anaphylaxis. If referral pathways become clearer, this could give first-opinion veterinarians a more defined next step after emergency care, especially for dogs with confirmed severe reactions and ongoing exposure risk. (gla.ac.uk)

The main caveat is that the published canine literature is still early-stage. The available studies are small, and at least one recent protocol paper notes that prior canine reports have shown systemic adverse event rates during venom immunotherapy ranging from 35% to 47%, even though most reactions were mild and manageable. The 2023 study’s authors suggested their lower event rate may relate in part to protocol design and avoidance of human serum albumin in extract preparation. That means uptake in general practice will likely depend on specialist oversight, careful case selection, and clearer real-world outcomes as more dogs are treated. (mdpi-res.com)

What to watch: The next signals to watch are whether Glasgow publishes outcomes from its UK caseload, whether other referral hospitals begin offering similar programs, and whether consensus starts to form around testing, induction protocols, maintenance duration, and which dogs should be considered for lifelong therapy. (gla.ac.uk)